Search

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Mini-hormone fights iron

Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.

Read more

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more

Navigate hematology

Building a career and a professional network can be overwhelming! Which career path should you take? How can you establish a meaningful mentoring relationship? Which funding is available and right for you? Who can you collaborate with? Is it time to publish?

On…

Read more

Pieter Sonneveld appointed Officer in the Order of Orange-Nassau

The EHA Board congratulates former EHA President Professor Pieter Sonneveld on his appointment as an Officer of the Order of Orange-Nassau by His Majesty King Willem-Alexander of the Netherlands.

Read more

Mesenchymal Stromal Cells (MSC)

The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…

Read more

Alliances & partnerships

EHA's approach to policy and regulatory affairs involves collaboration across medical professions and disciplines.

Read more